News headlines about Presbia (NASDAQ:LENS) have been trending somewhat negative recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Presbia earned a news sentiment score of -0.04 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 45.6818081690728 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Several brokerages recently weighed in on LENS. Zacks Investment Research raised shares of Presbia from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research note on Saturday, June 16th. HC Wainwright set a $6.00 target price on shares of Presbia and gave the stock a “buy” rating in a research note on Tuesday, May 29th. Finally, ValuEngine raised shares of Presbia from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

LENS traded down $0.09 during trading hours on Friday, hitting $1.90. 21,269 shares of the company’s stock were exchanged, compared to its average volume of 20,601. Presbia has a 12-month low of $1.79 and a 12-month high of $7.14.

Presbia Company Profile

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany.

Recommended Story: Understanding Stock Ratings

Insider Buying and Selling by Quarter for Presbia (NASDAQ:LENS)

Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.